tavapadon

News

AbbVie's Cerevel takeover delivers Parkinson's approval

The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.

News

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh

News

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w

AbbVie's Cerevel takeover delivers Parkinson's approval

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

Novartis abandons Fabhalta trial in lupus nephritis

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks